His primary research focus lies in the field of epigenetics. He employs cutting-edge techniques, including CRISPR library screening, ChIP-seq, ATAC-seq, Hi-C, and bioinformatics analysis, to investigate the intricacies of chromatin three-dimensional spatial organization and reconstruction. His ultimate goal is to unravel the mechanisms underlying changes in transcriptional and mutational landscapes during tumor progression. By doing so, he seeks to shed light on the causes of tumor occurrence and drug resistance, while also identifying potential biomarkers and therapeutic targets.

Professor Zifeng Wang has made significant contributions to scientific literature, publishing research papers as the first or corresponding author in reputable journals such as Adv Sci, Signal Transduct Target Ther, Clin Cancer Res, Cancer Commun, Oncogene, Cell Death Dis, J Biol Chem, and Cancer Lett. He has been the recipient of three National Natural Science Foundation of China projects and two Guangdong Provincial Natural Science Foundation projects. Additionally, he has played a key role in the execution of a 973 Project and a Youth 863 Project. Moreover, Professor Wang holds five authorized patents.

He has been appointed as a youth member of the 9th Immunology Committee of the Chinese Society of Pathophysiology, and he actively participates in various professional committees, including the Antineoplastic Drug Professional Committee of the Guangdong Anti-Cancer Association, the Tumor Pharmacology Professional Committee of the Guangdong Pharmacological Society, and the Tumor Oncology Branch of the Guangdong Translational Medicine Society.